Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Demant ASWILYY 94 EV-to-EBITDA is 20.60 as of Jul. 26, 2026, which is 14% above its 10-year median of 18.01. GuruFocus rates WILYY with a GF Score™ of 94/100 and a GF Value™ of $23.90 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Demant AS ranks worse than 70.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Demant AS's enterprise value is $11,716 Mil.
Demant AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $569 Mil. Therefore, Demant AS's EV-to-EBITDA for today is 20.60.
The historical rank and industry rank for Demant AS's EV-to-EBITDA or its related term are showing as below:
WILYY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.43 Med: 18.01 Max: 39.98
Current: 21.19
During the past 13 years, the highest EV-to-EBITDA of Demant AS was 39.98. The lowest was 10.43. And the median was 18.01.
WILYY's EV-to-EBITDA is ranked worse than 70.45% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.03
vs WILYY: 21.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Demant AS (OTCPK:WILYY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Demant AS's share price for today is $20.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Demant AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.567.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Demant AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Demant AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Demant AS EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Demant AS's EV-to-EBITDA falls into.
Demant AS's current Enterprise Value is $11,716 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Demant AS's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $569 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Demant AS (WILYY) has a EV-to-EBITDA of 20.60 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Demant AS. This is 14% above median its historical median of 18.01. Over the past decade, Demant AS's EV-to-EBITDA has ranged from 10.43 to 39.98. According to the industry distribution chart, Demant AS ranks #360 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 70.5%.
Is Demant AS's EV-to-EBITDA too high?
Demant AS's current EV-to-EBITDA of 20.60 is 14% above median its 10-year median of 18.01. Over the past 10 years, this metric has ranged from a low of 10.43 to a high of 39.98. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.03. Demant AS's value of 20.60 is 46.8% above this industry median. Based on the distribution chart, Demant AS ranks #360 out of 511 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Demant AS has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Demant AS's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Demant AS ranks #360 out of 511 companies for EV-to-EBITDA. This places Demant AS in the lower half of its industry. The industry median EV-to-EBITDA is 14.03. Demant AS's value of 20.60 is 46.8% above this benchmark. Historically, Demant AS's own EV-to-EBITDA has ranged from 10.43 to 39.98 over the past decade. While the company's 10-year median is 18.01 vs. the industry median of 14.03, Demant AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.03, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Demant AS's current EV-to-EBITDA of 20.60 is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Demant AS. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Demant AS's current EV-to-EBITDA is 20.60, which is 14% above median its own 10-year median of 18.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Based on GuruFocus' analysis, Demant AS (WILYY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.90, compared to a current price of $20.66 — trading 13.6% below its estimated fair value. The current EV-to-EBITDA is 20.60, which is 14% above median its 10-year median of 18.01 and 46.8% above the Medical Devices & Instruments industry median of 14.03. Demant AS's overall GF Score™ is 94/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Demant AS (WILYY), the current EV-to-EBITDA is 20.60 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Demant AS (WILYY) Overvalued in 2026?
Based on GuruFocus' analysis, Demant AS stock appears to be undervalued.
The current stock price of $20.66 is trading 13.6% below its estimated GF Value™ of $23.90.
GuruFocus considers Demant AS to be Modestly Undervalued.
Key valuation signals for WILYY:
EV-to-EBITDA: 20.60 (14% above median its 10-year median of 18.01)
GF Value™: $23.90 vs. price of $20.66 (13.6% below fair value)
Industry Position: 46.8% above the Medical Devices & Instruments median (#360 of 511)
No single metric tells the full story. See the WILYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
94GF Score
Get the complete analysis for WILYY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WILYY has been successfully added to your 
